Premium
Formyl peptide receptor type 2 agonists to kick‐start resolution pharmacology
Author(s) -
Perretti Mauro,
Godson Catherine
Publication year - 2020
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15212
Subject(s) - receptor , g protein coupled receptor , clinical pharmacology , pharmacology , neuroscience , medicine , terminology , computational biology , biology , linguistics , philosophy
One way to develop innovative approaches for the treatment of chronic diseases is to exploit the biology of the resolution of inflammation. With this terminology, we identify the integrated and complex network of mediators and pathways that ensure a timely and spatially regulated inflammatory response. Pro‐resolving mediators act on specific receptors. This provides an opportunity for developing a new arm of pharmacology we have termed “resolution pharmacology.” Here we present the reasoning behind the need to develop new medicines based on resolution and use a prototype GPCR as an example. Understanding how the formyl peptide receptor type 2 (FPR2) operates in a cell‐specific manner can guide the development of agonists as new therapeutics that could be of benefit as a therapy or co‐therapy for several diseases that affect our society. FPR2 agonists would be among the first drugs to establish “resolution pharmacology” as the pharmacological approach for the third decade of the millennium.